JP Morgan Chase
CYTO

JP Morgan Chase’s Altamira Therapeutics Ltd CYTO Stock Holding History

JP Morgan Chase’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5
Closed -$3K – 5838
2019
Q4 		$3K Buy
+5
New +$3.39K ﹤0.01% 5524
2016
Q2 		– Hold
0
– -$5K – 5017
2016
Q1 		– Hold
0
– – – 4381

Other funds holding CYTO

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JP Morgan Chase's CYTO Position: Q1 2020 in Review

JP Morgan Chase sold out of Altamira Therapeutics Ltd (CYTO) in Q1 2020, closing a stake of 5 shares — an estimated $3K sold.

JP Morgan Chase first reported a position in CYTO in Q4 2019 and held it in 1 quarter. The position peaked at $3K in Q4 2019. 4 funds tracked by Wall St. Rank hold CYTO as of Q1 2020.

  • JP Morgan Chase reported no remaining Altamira Therapeutics Ltd position as of Q1 2020 after selling out during the quarter.
  • JP Morgan Chase sold 5 Altamira Therapeutics Ltd shares in Q1 2020, an estimated $3K.
  • JP Morgan Chase first reported a position in Altamira Therapeutics Ltd in Q4 2019 and held it in 1 quarter.
  • JP Morgan Chase's Altamira Therapeutics Ltd position peaked at $3K in Q4 2019.
  • 4 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q1 2020.

Based on JP Morgan Chase's 13F filing for Q1 2020, filed 12 May 2020.